NVCR - Novocure/Zai Lab's TTFields therapy meets main goal in phase 2 gastric cancer trial

Novocure (NASDAQ:NVCR) and Zai Lab (NASDAQ:ZLAB) said a mid-stage study of their investigational device for Tumor Treating Fields (TTFields) met its main goal in patients with gastric cancer. TTFields are electric fields that are believed to disrupt cancer cell division. The companies said the phase 2 trial, dubbed EF-31, conducted in China, evaluated TTFields with standard-of-care (chemotherapy alone or in combination with trastuzumab, sold as Herceptin by Roche, for HER2-positive patients) as a first-line treatment in patients with gastroesophageal junction or gastric adenocarcinoma. The trial met its main goal of objective response rate (ORR) with supportive signals across secondary endpoints, the compaies said in a June 3 release. Confirmed ORR was 50% for patients treated with TTFields together with standard-of-care chemotherapy. Initial analysis was conducted with a median follow-up period of 8.6 months. The therapy reduced the risk of disease progression by a median 7.8 months. Duration of response was 10.3 months, the companies added. The companies noted

For further details see:

Novocure/Zai Lab's TTFields therapy meets main goal in phase 2 gastric cancer trial